Interesting May Stock Options for Pfizer

Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Pfizer ( PFE). So this week we highlight one interesting put contract, and one interesting call contract, from the May expiration for PFE. The put contract our YieldBoost algorithm identified as particularly interesting, is at the $31 strike, which has a bid at the time of this writing of 60 cents. Collecting that bid as the premium represents a 1.9% return against the $31 commitment, or a 10.4% annualized rate of return (at Stock Options Channel we call this the YieldBoost).

Top YieldBoost PFE Puts »

Selling a put does not give an investor access to PFE's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. So unless Pfizer Inc sees its shares decline 4.5% and the contract is exercised (resulting in a cost basis of $30.40 per share before broker commissions, subtracting the 60 cents from $31), the only upside to the put seller is from collecting that premium for the 10.4% annualized rate of return.

Interestingly, that annualized 10.4% figure actually exceeds the 3.2% annualized dividend paid by Pfizer Inc by 7.2%, based on the current share price of $32.49. And yet, if an investor was to buy the stock at the going market price in order to collect the dividend, there is greater downside because the stock would have to lose 4.47% to reach the $31 strike price.

Always important when discussing dividends is the fact that, in general, dividend amounts are not always predictable and tend to follow the ups and downs of profitability at each company. In the case of Pfizer Inc, looking at the dividend history chart for PFE below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 3.2% annualized dividend yield.

If you liked this article you might like

Dow, S&P 500 Set New Records as Fed Moves to Unwind Balance Sheet

Stocks In Negative Territory as Chances for December Hike Surge

The Wait for 'Milestone' Fed Meeting Keeps Stocks in Flux

The 6 Medications Being Used to Tackle the Opioid Epidemic